Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
Basel, November 13, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of Cosentyx® (secukinumab) for adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapy.6 If approved by the European Commission (EC), Cosentyx would become the only interleukin-17A (IL-17A) inhibitor approved for adolescent HS in Europe and the first innovative biologic treatment option for this population in nearly a decade, addressing a significant unmet need where treatment options remain limited.1,2,7,8
Covered in this story
Analyst targets on Novartis
- Deutsche Bank: at CHF132 · target CHF115 by Nov 2027 · Sell via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $NOVN.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Novartis →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.